<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03404674</url>
  </required_header>
  <id_info>
    <org_study_id>VAC-050</org_study_id>
    <nct_id>NCT03404674</nct_id>
  </id_info>
  <brief_title>Dose Escalating Study of a Prototype CS6 Subunit Vaccine With a Modified Heat-labile Enterotoxin From Enterotoxigenic Escherichia Coli (ETEC)</brief_title>
  <official_title>A Phase 1 Dose Escalating Study of a Prototype CS6 Subunit Vaccine With a Modified Heat-labile Enterotoxin From Enterotoxigenic Escherichia Coli (ETEC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Naval Medical Research Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Walter Reed Army Institute of Research Clinical Trials Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PATH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety of a prototype Coli surface antigen 6 (CS6) subunit&#xD;
      vaccine (CssBA) alone or in combination with Escherichia coli double mutant heat labile toxin&#xD;
      (dmLT) given by intramuscular (IM) injection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label clinical trial in which a total of 50 participants will receive three&#xD;
      injections of either CssBA alone, dmLT alone or CssBA + dmLT. The vaccine will be&#xD;
      administered via IM injection to alternating deltoid regions on days 1, 22, and 43. Each&#xD;
      participant will receive the same dose at each vaccination dependent upon group assignment.&#xD;
      Group A is considered a pilot group in which all 3 doses will be administered and&#xD;
      participants monitored for safety 7 days after the third vaccination, prior to the enrollment&#xD;
      of participants in Group B.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 16, 2018</start_date>
  <completion_date type="Actual">March 26, 2019</completion_date>
  <primary_completion_date type="Actual">March 26, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Solicited Adverse Events</measure>
    <time_frame>From first vaccination to 28 days after the third vaccination, 71 days.</time_frame>
    <description>Solicited adverse events included vaccine site pain, vaccine site pruritus, vaccine site rash/eruption, vaccine site swelling, vaccine site tenderness, fever, headache, diarrhea, arthralgia, myalgia, malaise, nausea, and vomiting.&#xD;
Adverse events were assessed for severity by the investigator according to the following:&#xD;
Mild (Grade 1): Does not interfere with routine activities, minimal level of discomfort&#xD;
Moderate (Grade 2): Interferes with routine activities, moderate level of discomfort&#xD;
Severe (Grade 3): Unable to perform routine activities, significant level of discomfort&#xD;
Potentially life-threatening (Grade 4): Hospitalization or emergency room (ER) visit for potentially life-threatening event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Unsolicited Adverse Events</measure>
    <time_frame>From first vaccination to 28 days after the third vaccination, 71 days.</time_frame>
    <description>Adverse events were assessed for severity by the investigator according to the following:&#xD;
Mild (Grade 1): Does not interfere with routine activities Minimal level of discomfort&#xD;
Moderate (Grade 2): Interferes with routine activities Moderate level of discomfort&#xD;
Severe (Grade 3): Unable to perform routine activities Significant level of discomfort&#xD;
Potentially life-threatening (Grade 4): Hospitalization or emergency room (ER) visit for potentially life-threatening event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Serum Immunologic Response to Coli Surface Antigen 6 (CS6)</measure>
    <time_frame>Baseline (Day 1 predose), Days 22 and 43 predose, and Day 70</time_frame>
    <description>Serum samples were assayed for immunoglobulin G (IgG) and immunoglobulin A (IgA) antibody titers against CS6 using an enzyme-linked Immunosorbent assay (ELISA). Immunologic response was defined as a ≥ 4-fold increase in reciprocal endpoint titer between Baseline and any post-vaccination sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Serum Immunologic Response to Labile Toxin</measure>
    <time_frame>Baseline (Day 1 predose), Days 22 and 43 predose, and Day 70</time_frame>
    <description>Serum samples were assayed for immunoglobulin G (IgG) and immunoglobulin A (IgA) antibody titers against labile toxin using an enzyme-linked Immunosorbent assay (ELISA). Immunologic response was defined as a ≥ 4-fold increase in reciprocal endpoint titer between Baseline and any post-vaccination sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Mucosal Immunologic Response to Coli Surface Antigen 6 (CS6)</measure>
    <time_frame>Baseline (Day 1 pre-dose), Days 8 and 29 predose, and Day 50</time_frame>
    <description>Peripheral blood mononuclear cells (PBMCs) were collected to determine antibody responses from lymphocyte supernatant against CS6 at Baseline and 7 days after each vaccination. Antibody in lymphocyte supernatant (ALS) is an indirect quantification of antibody secreting cells (ASC) activated in the mucosa that circulate in the peripheral blood about seven days post-mucosal immunization/infection. After incubation, lymphocyte supernatant was assayed for antigen-specific IgG and IgA antibodies using ELISA.&#xD;
A positive ALS response was defined as a four-fold rise in antibody titers between Baseline and any post vaccination sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Mucosal Immunologic Response to Labile Toxin</measure>
    <time_frame>Baseline (Day 1 pre-dose), Days 8 and 29 predose, and Day 50</time_frame>
    <description>Peripheral blood mononuclear cells (PBMCs) were collected to determine antibody responses from lymphocyte supernatant against labile toxin at Baseline and 7 days after each vaccination. Antibody in lymphocyte supernatant (ALS) is an indirect quantification of antibody secreting cells (ASC) activated in the mucosa that circulate in the peripheral blood about seven days post-mucosal immunization/infection. After incubation, lymphocyte supernatant was assayed for antigen-specific IgG and IgA antibodies using ELISA.&#xD;
A positive ALS response was defined as a four-fold rise in antibody titers between Baseline and any post vaccination sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer of Serum Anti-CS6 Immunoglobulin G Antibodies</measure>
    <time_frame>Days 1, 22, and 43 pre-vaccination, and Day 70</time_frame>
    <description>Serum samples were assayed for IgG antibody titers against CS6 using an enzyme-linked Immunosorbent assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer of Serum Anti-CS6 Immunoglobulin A Antibodies</measure>
    <time_frame>Days 1, 22, and 43 pre-vaccination, and Day 70</time_frame>
    <description>Serum samples were assayed for IgA antibody titers against CS6 using an enzyme-linked Immunosorbent assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer of Serum Anti-LT Immunoglobulin G Antibodies</measure>
    <time_frame>Days 1, 22, and 43 pre-vaccination, and Day 70</time_frame>
    <description>Serum samples were assayed for IgG antibody titers against labile toxin using an enzyme-linked Immunosorbent assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer of Serum Anti-LT Immunoglobulin A Antibodies</measure>
    <time_frame>Days 1, 22, and 43 pre-vaccination, and Day 70</time_frame>
    <description>Serum samples were assayed for IgA antibody titers against labile toxin using an enzyme-linked Immunosorbent assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer of Antibody Lymphocyte Supernatant Anti-CS6 Immunoglobulin G Antibodies</measure>
    <time_frame>Days 1, 8, 29 and 50</time_frame>
    <description>Lymphocyte supernatant was assayed for IgG antibody titers against CS6 using ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer of Antibody Lymphocyte Supernatant Anti-CS6 Immunoglobulin A Antibodies</measure>
    <time_frame>Days 1, 8, 29, and 50</time_frame>
    <description>Lymphocyte supernatant was assayed for IgA antibody titers against CS6 using ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer of Antibody Lymphocyte Supernatant Anti-LT Immunoglobulin G Antibodies</measure>
    <time_frame>Days 1, 8, 29, and 50</time_frame>
    <description>Lymphocyte supernatant was assayed for IgG antibody titers against labile toxin using ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer of Antibody Lymphocyte Supernatant Anti-LT Immunoglobulin A Antibodies</measure>
    <time_frame>Days 1, 8, 29, and 50</time_frame>
    <description>Lymphocyte supernatant was assayed for IgA antibody titers against labile toxin using ELISA.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Diarrhea</condition>
  <arm_group>
    <arm_group_label>Group A1: CssBA 5 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received an intramuscular injection of 5 ug CssBA on days 1, 22, and 43.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A2: DmLT 100 ng</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received an intramuscular injection of 100 ng DmLT on days 1, 22, and 43.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: CssBA 5 ug + DmLT 100 ng</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received an intramuscular injection of 5 ug CssBA + 100 ng dmLT on days 1, 22, and 43.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C: CssBA 5 ug + DmLT 500 ng</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received an intramuscular injection of 5 ug CssBA + 500 ng dmLT on days 1, 22, and 43.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D: CssBA 15 ug + DmLT 500 ng</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received an intramuscular injection of 15 ug CssBA + 500 ng dmLT on days 1, 22, and 43.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E: CssBA 45 ug + DmLT 500 ng</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received an intramuscular injection of 45 ug CssBA + 500 ng dmLT on days 1, 22, and 43.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CssBA</intervention_name>
    <description>Recombinant enterotoxigenic Escherichia coli (ETEC) surface antigen 6 containing modified structural subunits A and B</description>
    <arm_group_label>Group A1: CssBA 5 ug</arm_group_label>
    <arm_group_label>Group B: CssBA 5 ug + DmLT 100 ng</arm_group_label>
    <arm_group_label>Group C: CssBA 5 ug + DmLT 500 ng</arm_group_label>
    <arm_group_label>Group D: CssBA 15 ug + DmLT 500 ng</arm_group_label>
    <arm_group_label>Group E: CssBA 45 ug + DmLT 500 ng</arm_group_label>
    <other_name>spd_dsc16Bntd14CssBAB7A[His]₆</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>dmLT</intervention_name>
    <description>Escherichia coli double mutant heat-labile toxin with mutations at amino acids 192 and 211</description>
    <arm_group_label>Group A2: DmLT 100 ng</arm_group_label>
    <arm_group_label>Group B: CssBA 5 ug + DmLT 100 ng</arm_group_label>
    <arm_group_label>Group C: CssBA 5 ug + DmLT 500 ng</arm_group_label>
    <arm_group_label>Group D: CssBA 15 ug + DmLT 500 ng</arm_group_label>
    <arm_group_label>Group E: CssBA 45 ug + DmLT 500 ng</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy, adult, male or female, age 18 to 45 years (inclusive) at the time of&#xD;
             enrollment.&#xD;
&#xD;
          2. Completion and review of comprehension test (achieved &gt; 70% accuracy).&#xD;
&#xD;
          3. Signed informed consent document.&#xD;
&#xD;
          4. Available for the required follow-up period and scheduled clinic visits.&#xD;
&#xD;
          5. Women: Negative pregnancy test with understanding (through informed consent process)&#xD;
             to not become pregnant during the study or within three (3) months following last&#xD;
             vaccination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Health problems (for example, intercurrent febrile illness, chronic medical conditions&#xD;
             such as psychiatric conditions, diabetes mellitus, hypertension or any other condition&#xD;
             that might place the subject at increased risk of adverse events) - study clinicians,&#xD;
             in consultation with the PI, will use clinical judgment on a case-by-case basis to&#xD;
             assess safety risks under this criterion. The PI will consult with the Research&#xD;
             Monitor as appropriate.&#xD;
&#xD;
          2. Clinically significant abnormalities on physical examination.&#xD;
&#xD;
          3. Immunosuppressive drugs (use of systemic corticosteroids or chemotherapeutics that may&#xD;
             influence antibody development) or illness (including immunoglobulin A [IgA]&#xD;
             deficiency, defined by serum IgA &lt; 7 mg/dL).&#xD;
&#xD;
          4. Women who are pregnant or planning to become pregnant during the study period plus&#xD;
             three (3) months beyond the last received dose and currently nursing women.&#xD;
&#xD;
          5. Participation in research involving another investigational product (defined as&#xD;
             receipt of investigational product or exposure to invasive investigational device) 30&#xD;
             days before planned date of first vaccination or anytime through the last study safety&#xD;
             visit.&#xD;
&#xD;
          6. Positive blood test for Hepatitis B surface antigen (HBsAg), Hepatitis C virus (HCV),&#xD;
             human immunodeficiency virus (HIV)-1/2.&#xD;
&#xD;
          7. Clinically significant abnormalities on basic laboratory screening.&#xD;
&#xD;
          8. Exclusionary skin disease history/findings that would confound assessment or prevent&#xD;
             appropriate local monitoring of adverse events (AEs), or possibly increase the risk of&#xD;
             a local AE&#xD;
&#xD;
          9. History of chronic skin disease (clinician judgement)&#xD;
&#xD;
         10. Acute skin infection/eruptions on the upper arms including fungal infections, severe&#xD;
             acne or active contact dermatitis&#xD;
&#xD;
         11. Allergies that may increase the risk of AEs&#xD;
&#xD;
         12. Regular use (weekly or more often) of antidiarrheal, anti-constipation, or antacid&#xD;
             therapy&#xD;
&#xD;
         13. Abnormal stool pattern (fewer than 3 stools per week or more than 3 stools per day) on&#xD;
             a regular basis; loose or liquid stools on other than an occasional basis&#xD;
&#xD;
         14. History of microbiologically confirmed ETEC or cholera infection in the last 3 years&#xD;
&#xD;
         15. Travel to countries where ETEC or V. cholerae or other enteric infections are endemic&#xD;
             (most of the developing world) within 3 years prior to dosing (clinician judgement)&#xD;
&#xD;
         16. Symptoms consistent with Travelers' Diarrhea or concurrent with travel to countries&#xD;
             where ETEC infection is endemic (most of the developing world) within 3 years prior to&#xD;
             dosing, OR planned travel to endemic countries during the length of the study&#xD;
&#xD;
         17. Vaccination for or ingestion of ETEC, cholera, or E. coli heat labile toxin within 3&#xD;
             years prior to dosing&#xD;
&#xD;
         18. Occupation involving handling of ETEC or V. cholerae currently, or in the past 3 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tida K Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Naval Medical Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Walter Reed Army Institute of Research Clinical Trial Center</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>January 10, 2018</study_first_submitted>
  <study_first_submitted_qc>January 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2018</study_first_posted>
  <results_first_submitted>December 10, 2020</results_first_submitted>
  <results_first_submitted_qc>December 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 6, 2021</results_first_posted>
  <last_update_submitted>December 10, 2020</last_update_submitted>
  <last_update_submitted_qc>December 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ETEC</keyword>
  <keyword>Escherichia coli</keyword>
  <keyword>enteric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 31, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT03404674/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 25, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT03404674/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy adult men and women, civilian and active-duty military, were recruited from the Baltimore/Washington, DC area through the Walter Reed Army Institute of Research (WRAIR) Clinical Trials Center (CTC) by the use of advertisement in multiple media formats.</recruitment_details>
      <pre_assignment_details>Participants were sequentially enrolled to received either recombinant enterotoxigenic Escherichia coli (ETEC) surface antigen 6 vaccine (CssBA) alone, Escherichia coli double mutant heat-labile toxin (dmLT) alone, or CssBA co-administered with dmLT. Participants were to receive 3 vaccinations at the same dose of their assigned treatment.&#xD;
Enrollment of subsequent groups was dependent on safety measured in the first 7 days after the third vaccination of the previous group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group A1: CssBA 5 µg</title>
          <description>Participants received an intramuscular injection of 5 µg CssBA on days 1, 22, and 43.</description>
        </group>
        <group group_id="P2">
          <title>Group A2: DmLT 100 ng</title>
          <description>Participants received an intramuscular injection of 100 ng DmLT on days 1, 22, and 43.</description>
        </group>
        <group group_id="P3">
          <title>Group B: CssBA 5 µg + DmLT 100 ng</title>
          <description>Participants received an intramuscular injection of 5 µg CssBA co-administered with 100 ng dmLT on days 1, 22, and 43.</description>
        </group>
        <group group_id="P4">
          <title>Group C: CssBA 5 µg + DmLT 500 ng</title>
          <description>Participants received an intramuscular injection of 5 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
        </group>
        <group group_id="P5">
          <title>Group D: CssBA 15 µg + DmLT 500 ng</title>
          <description>Participants received an intramuscular injection of 15 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
        </group>
        <group group_id="P6">
          <title>Group E: CssBA 45 µg + DmLT 500 ng</title>
          <description>Participants received an intramuscular injection of 45 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Dose 2</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Dose 3</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Inability to Attend Future Visits</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Behavioral Problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Started a Medication that Precluded Eligibility</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled participants</population>
      <group_list>
        <group group_id="B1">
          <title>Group A1: CssBA 5 µg</title>
          <description>Participants received an intramuscular injection of 5 µg CssBA on days 1, 22, and 43.</description>
        </group>
        <group group_id="B2">
          <title>Group A2: DmLT 100 ng</title>
          <description>Participants received an intramuscular injection of 100 ng DmLT on days 1, 22, and 43.</description>
        </group>
        <group group_id="B3">
          <title>Group B: CssBA 5 µg + DmLT 100 ng</title>
          <description>Participants received an intramuscular injection of 5 µg CssBA co-administered with 100 ng dmLT on days 1, 22, and 43.</description>
        </group>
        <group group_id="B4">
          <title>Group C: CssBA 5 µg + DmLT 500 ng</title>
          <description>Participants received an intramuscular injection of 5 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
        </group>
        <group group_id="B5">
          <title>Group D: CssBA 15 µg + DmLT 500 ng</title>
          <description>Participants received an intramuscular injection of 15 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
        </group>
        <group group_id="B6">
          <title>Group E: CssBA 45 µg + DmLT 500 ng</title>
          <description>Participants received an intramuscular injection of 45 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="10"/>
            <count group_id="B6" value="10"/>
            <count group_id="B7" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" lower_limit="30" upper_limit="41"/>
                    <measurement group_id="B2" value="29" lower_limit="27" upper_limit="37"/>
                    <measurement group_id="B3" value="29.5" lower_limit="26" upper_limit="32"/>
                    <measurement group_id="B4" value="31.5" lower_limit="27" upper_limit="37"/>
                    <measurement group_id="B5" value="28" lower_limit="22" upper_limit="38"/>
                    <measurement group_id="B6" value="29.5" lower_limit="25" upper_limit="33"/>
                    <measurement group_id="B7" value="30" lower_limit="26" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Multi-race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Solicited Adverse Events</title>
        <description>Solicited adverse events included vaccine site pain, vaccine site pruritus, vaccine site rash/eruption, vaccine site swelling, vaccine site tenderness, fever, headache, diarrhea, arthralgia, myalgia, malaise, nausea, and vomiting.&#xD;
Adverse events were assessed for severity by the investigator according to the following:&#xD;
Mild (Grade 1): Does not interfere with routine activities, minimal level of discomfort&#xD;
Moderate (Grade 2): Interferes with routine activities, moderate level of discomfort&#xD;
Severe (Grade 3): Unable to perform routine activities, significant level of discomfort&#xD;
Potentially life-threatening (Grade 4): Hospitalization or emergency room (ER) visit for potentially life-threatening event</description>
        <time_frame>From first vaccination to 28 days after the third vaccination, 71 days.</time_frame>
        <population>All participants who received one or more doses of the study drugs</population>
        <group_list>
          <group group_id="O1">
            <title>Group A1: CssBA 5 µg</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA on days 1, 22, and 43.</description>
          </group>
          <group group_id="O2">
            <title>Group A2: DmLT 100 ng</title>
            <description>Participants received an intramuscular injection of 100 ng DmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O3">
            <title>Group B: CssBA 5 µg + DmLT 100 ng</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA co-administered with 100 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O4">
            <title>Group C: CssBA 5 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O5">
            <title>Group D: CssBA 15 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 15 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O6">
            <title>Group E: CssBA 45 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 45 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Adverse Events</title>
          <description>Solicited adverse events included vaccine site pain, vaccine site pruritus, vaccine site rash/eruption, vaccine site swelling, vaccine site tenderness, fever, headache, diarrhea, arthralgia, myalgia, malaise, nausea, and vomiting.&#xD;
Adverse events were assessed for severity by the investigator according to the following:&#xD;
Mild (Grade 1): Does not interfere with routine activities, minimal level of discomfort&#xD;
Moderate (Grade 2): Interferes with routine activities, moderate level of discomfort&#xD;
Severe (Grade 3): Unable to perform routine activities, significant level of discomfort&#xD;
Potentially life-threatening (Grade 4): Hospitalization or emergency room (ER) visit for potentially life-threatening event</description>
          <population>All participants who received one or more doses of the study drugs</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Life-threatening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Serum Immunologic Response to Coli Surface Antigen 6 (CS6)</title>
        <description>Serum samples were assayed for immunoglobulin G (IgG) and immunoglobulin A (IgA) antibody titers against CS6 using an enzyme-linked Immunosorbent assay (ELISA). Immunologic response was defined as a ≥ 4-fold increase in reciprocal endpoint titer between Baseline and any post-vaccination sample.</description>
        <time_frame>Baseline (Day 1 predose), Days 22 and 43 predose, and Day 70</time_frame>
        <population>Participants who received at least 2 vaccine doses and had at least 2 post-vaccine samples available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A1: CssBA 5 µg</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA on days 1, 22, and 43.</description>
          </group>
          <group group_id="O2">
            <title>Group A2: DmLT 100 ng</title>
            <description>Participants received an intramuscular injection of 100 ng DmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O3">
            <title>Group B: CssBA 5 µg + DmLT 100 ng</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA co-administered with 100 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O4">
            <title>Group C: CssBA 5 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O5">
            <title>Group D: CssBA 15 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 15 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O6">
            <title>Group E: CssBA 45 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 45 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Serum Immunologic Response to Coli Surface Antigen 6 (CS6)</title>
          <description>Serum samples were assayed for immunoglobulin G (IgG) and immunoglobulin A (IgA) antibody titers against CS6 using an enzyme-linked Immunosorbent assay (ELISA). Immunologic response was defined as a ≥ 4-fold increase in reciprocal endpoint titer between Baseline and any post-vaccination sample.</description>
          <population>Participants who received at least 2 vaccine doses and had at least 2 post-vaccine samples available.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IgA response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="44.4"/>
                    <measurement group_id="O5" value="30.0"/>
                    <measurement group_id="O6" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="77.8"/>
                    <measurement group_id="O4" value="100.0"/>
                    <measurement group_id="O5" value="100.0"/>
                    <measurement group_id="O6" value="90.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Serum Immunologic Response to Labile Toxin</title>
        <description>Serum samples were assayed for immunoglobulin G (IgG) and immunoglobulin A (IgA) antibody titers against labile toxin using an enzyme-linked Immunosorbent assay (ELISA). Immunologic response was defined as a ≥ 4-fold increase in reciprocal endpoint titer between Baseline and any post-vaccination sample.</description>
        <time_frame>Baseline (Day 1 predose), Days 22 and 43 predose, and Day 70</time_frame>
        <population>Participants who received at least 2 vaccine doses and had at least 2 post-vaccine samples available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A1: CssBA 5 µg</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA on days 1, 22, and 43.</description>
          </group>
          <group group_id="O2">
            <title>Group A2: DmLT 100 ng</title>
            <description>Participants received an intramuscular injection of 100 ng DmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O3">
            <title>Group B: CssBA 5 µg + DmLT 100 ng</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA co-administered with 100 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O4">
            <title>Group C: CssBA 5 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O5">
            <title>Group D: CssBA 15 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 15 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O6">
            <title>Group E: CssBA 45 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 45 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Serum Immunologic Response to Labile Toxin</title>
          <description>Serum samples were assayed for immunoglobulin G (IgG) and immunoglobulin A (IgA) antibody titers against labile toxin using an enzyme-linked Immunosorbent assay (ELISA). Immunologic response was defined as a ≥ 4-fold increase in reciprocal endpoint titer between Baseline and any post-vaccination sample.</description>
          <population>Participants who received at least 2 vaccine doses and had at least 2 post-vaccine samples available.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IgA response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="22.2"/>
                    <measurement group_id="O4" value="77.8"/>
                    <measurement group_id="O5" value="50.0"/>
                    <measurement group_id="O6" value="70.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="66.7"/>
                    <measurement group_id="O4" value="100.0"/>
                    <measurement group_id="O5" value="90.0"/>
                    <measurement group_id="O6" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Mucosal Immunologic Response to Coli Surface Antigen 6 (CS6)</title>
        <description>Peripheral blood mononuclear cells (PBMCs) were collected to determine antibody responses from lymphocyte supernatant against CS6 at Baseline and 7 days after each vaccination. Antibody in lymphocyte supernatant (ALS) is an indirect quantification of antibody secreting cells (ASC) activated in the mucosa that circulate in the peripheral blood about seven days post-mucosal immunization/infection. After incubation, lymphocyte supernatant was assayed for antigen-specific IgG and IgA antibodies using ELISA.&#xD;
A positive ALS response was defined as a four-fold rise in antibody titers between Baseline and any post vaccination sample.</description>
        <time_frame>Baseline (Day 1 pre-dose), Days 8 and 29 predose, and Day 50</time_frame>
        <population>Participants who received at least 2 vaccine doses and had at least 2 post-vaccine samples available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A1: CssBA 5 µg</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA on days 1, 22, and 43.</description>
          </group>
          <group group_id="O2">
            <title>Group A2: DmLT 100 ng</title>
            <description>Participants received an intramuscular injection of 100 ng DmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O3">
            <title>Group B: CssBA 5 µg + DmLT 100 ng</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA co-administered with 100 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O4">
            <title>Group C: CssBA 5 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O5">
            <title>Group D: CssBA 15 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 15 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O6">
            <title>Group E: CssBA 45 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 45 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Mucosal Immunologic Response to Coli Surface Antigen 6 (CS6)</title>
          <description>Peripheral blood mononuclear cells (PBMCs) were collected to determine antibody responses from lymphocyte supernatant against CS6 at Baseline and 7 days after each vaccination. Antibody in lymphocyte supernatant (ALS) is an indirect quantification of antibody secreting cells (ASC) activated in the mucosa that circulate in the peripheral blood about seven days post-mucosal immunization/infection. After incubation, lymphocyte supernatant was assayed for antigen-specific IgG and IgA antibodies using ELISA.&#xD;
A positive ALS response was defined as a four-fold rise in antibody titers between Baseline and any post vaccination sample.</description>
          <population>Participants who received at least 2 vaccine doses and had at least 2 post-vaccine samples available.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IgA response</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="88.9"/>
                    <measurement group_id="O5" value="80.0"/>
                    <measurement group_id="O6" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG response</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="88.9"/>
                    <measurement group_id="O5" value="100.0"/>
                    <measurement group_id="O6" value="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Mucosal Immunologic Response to Labile Toxin</title>
        <description>Peripheral blood mononuclear cells (PBMCs) were collected to determine antibody responses from lymphocyte supernatant against labile toxin at Baseline and 7 days after each vaccination. Antibody in lymphocyte supernatant (ALS) is an indirect quantification of antibody secreting cells (ASC) activated in the mucosa that circulate in the peripheral blood about seven days post-mucosal immunization/infection. After incubation, lymphocyte supernatant was assayed for antigen-specific IgG and IgA antibodies using ELISA.&#xD;
A positive ALS response was defined as a four-fold rise in antibody titers between Baseline and any post vaccination sample.</description>
        <time_frame>Baseline (Day 1 pre-dose), Days 8 and 29 predose, and Day 50</time_frame>
        <population>Participants who received at least 2 vaccine doses and had at least 2 post-vaccine samples available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A1: CssBA 5 µg</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA on days 1, 22, and 43.</description>
          </group>
          <group group_id="O2">
            <title>Group A2: DmLT 100 ng</title>
            <description>Participants received an intramuscular injection of 100 ng DmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O3">
            <title>Group B: CssBA 5 µg + DmLT 100 ng</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA co-administered with 100 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O4">
            <title>Group C: CssBA 5 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O5">
            <title>Group D: CssBA 15 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 15 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O6">
            <title>Group E: CssBA 45 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 45 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Mucosal Immunologic Response to Labile Toxin</title>
          <description>Peripheral blood mononuclear cells (PBMCs) were collected to determine antibody responses from lymphocyte supernatant against labile toxin at Baseline and 7 days after each vaccination. Antibody in lymphocyte supernatant (ALS) is an indirect quantification of antibody secreting cells (ASC) activated in the mucosa that circulate in the peripheral blood about seven days post-mucosal immunization/infection. After incubation, lymphocyte supernatant was assayed for antigen-specific IgG and IgA antibodies using ELISA.&#xD;
A positive ALS response was defined as a four-fold rise in antibody titers between Baseline and any post vaccination sample.</description>
          <population>Participants who received at least 2 vaccine doses and had at least 2 post-vaccine samples available.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IgA response</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="22.2"/>
                    <measurement group_id="O4" value="77.8"/>
                    <measurement group_id="O5" value="90.0"/>
                    <measurement group_id="O6" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG response</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="100.0"/>
                    <measurement group_id="O5" value="100.0"/>
                    <measurement group_id="O6" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer of Serum Anti-CS6 Immunoglobulin G Antibodies</title>
        <description>Serum samples were assayed for IgG antibody titers against CS6 using an enzyme-linked Immunosorbent assay (ELISA).</description>
        <time_frame>Days 1, 22, and 43 pre-vaccination, and Day 70</time_frame>
        <population>Participants who received at least 2 vaccine doses and had at least 2 post-vaccine samples available, and with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A1: CssBA 5 µg</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA on days 1, 22, and 43.</description>
          </group>
          <group group_id="O2">
            <title>Group A2: DmLT 100 ng</title>
            <description>Participants received an intramuscular injection of 100 ng DmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O3">
            <title>Group B: CssBA 5 µg + DmLT 100 ng</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA co-administered with 100 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O4">
            <title>Group C: CssBA 5 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O5">
            <title>Group D: CssBA 15 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 15 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O6">
            <title>Group E: CssBA 45 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 45 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer of Serum Anti-CS6 Immunoglobulin G Antibodies</title>
          <description>Serum samples were assayed for IgG antibody titers against CS6 using an enzyme-linked Immunosorbent assay (ELISA).</description>
          <population>Participants who received at least 2 vaccine doses and had at least 2 post-vaccine samples available, and with available data at each time point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (pre-vaccination)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.0" lower_limit="18.2" upper_limit="83.6"/>
                    <measurement group_id="O2" value="29.6" lower_limit="17.5" upper_limit="50.1"/>
                    <measurement group_id="O3" value="39.1" lower_limit="22.2" upper_limit="69.1"/>
                    <measurement group_id="O4" value="36.9" lower_limit="20.5" upper_limit="66.6"/>
                    <measurement group_id="O5" value="40.5" lower_limit="24.6" upper_limit="66.7"/>
                    <measurement group_id="O6" value="51.5" lower_limit="26.1" upper_limit="101.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 (pre-vaccination)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.2" lower_limit="17.8" upper_limit="90.8"/>
                    <measurement group_id="O2" value="34.1" lower_limit="12.9" upper_limit="90.7"/>
                    <measurement group_id="O3" value="28.2" lower_limit="21.6" upper_limit="36.8"/>
                    <measurement group_id="O4" value="81.2" lower_limit="16.6" upper_limit="396.6"/>
                    <measurement group_id="O5" value="80.1" lower_limit="39.4" upper_limit="162.9"/>
                    <measurement group_id="O6" value="107.1" lower_limit="28.3" upper_limit="405.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (pre-vacination)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.4" lower_limit="16.9" upper_limit="195"/>
                    <measurement group_id="O2" value="46.6" lower_limit="14.5" upper_limit="149.8"/>
                    <measurement group_id="O3" value="108.9" lower_limit="54.3" upper_limit="218.4"/>
                    <measurement group_id="O4" value="513.5" lower_limit="77.2" upper_limit="3415.4"/>
                    <measurement group_id="O5" value="288.2" lower_limit="100.2" upper_limit="829.2"/>
                    <measurement group_id="O6" value="958.3" lower_limit="235.9" upper_limit="3893.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 70 (28 days after last vaccination)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.3" lower_limit="19.0" upper_limit="346.7"/>
                    <measurement group_id="O2" value="29.4" lower_limit="17.8" upper_limit="48.5"/>
                    <measurement group_id="O3" value="695.3" lower_limit="182.1" upper_limit="2655.3"/>
                    <measurement group_id="O4" value="4631.2" lower_limit="1462.3" upper_limit="14667.6"/>
                    <measurement group_id="O5" value="2520.4" lower_limit="1199.2" upper_limit="5297.2"/>
                    <measurement group_id="O6" value="5167.1" lower_limit="1298.8" upper_limit="20556.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer of Serum Anti-CS6 Immunoglobulin A Antibodies</title>
        <description>Serum samples were assayed for IgA antibody titers against CS6 using an enzyme-linked Immunosorbent assay (ELISA).</description>
        <time_frame>Days 1, 22, and 43 pre-vaccination, and Day 70</time_frame>
        <population>Participants who received at least 2 vaccine doses and had at least 2 post-vaccine samples available, and with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A1: CssBA 5 µg</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA on days 1, 22, and 43.</description>
          </group>
          <group group_id="O2">
            <title>Group A2: DmLT 100 ng</title>
            <description>Participants received an intramuscular injection of 100 ng DmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O3">
            <title>Group B: CssBA 5 µg + DmLT 100 ng</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA co-administered with 100 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O4">
            <title>Group C: CssBA 5 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O5">
            <title>Group D: CssBA 15 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 15 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O6">
            <title>Group E: CssBA 45 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 45 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer of Serum Anti-CS6 Immunoglobulin A Antibodies</title>
          <description>Serum samples were assayed for IgA antibody titers against CS6 using an enzyme-linked Immunosorbent assay (ELISA).</description>
          <population>Participants who received at least 2 vaccine doses and had at least 2 post-vaccine samples available, and with available data at each time point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (pre-vaccination)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="269.9" lower_limit="133.6" upper_limit="545.1"/>
                    <measurement group_id="O2" value="213.4" lower_limit="73.0" upper_limit="623.6"/>
                    <measurement group_id="O3" value="308.5" lower_limit="181.4" upper_limit="524.4"/>
                    <measurement group_id="O4" value="330.0" lower_limit="176.1" upper_limit="618.6"/>
                    <measurement group_id="O5" value="368.2" lower_limit="192.3" upper_limit="705.0"/>
                    <measurement group_id="O6" value="370.8" lower_limit="180.9" upper_limit="760.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 (pre-vaccination)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="294.3" lower_limit="128.7" upper_limit="672.9"/>
                    <measurement group_id="O2" value="215" lower_limit="64.9" upper_limit="712.4"/>
                    <measurement group_id="O3" value="285.1" lower_limit="172.9" upper_limit="469.9"/>
                    <measurement group_id="O4" value="846.9" lower_limit="189.1" upper_limit="3792.6"/>
                    <measurement group_id="O5" value="408.0" lower_limit="223.1" upper_limit="746.1"/>
                    <measurement group_id="O6" value="523.5" lower_limit="262.0" upper_limit="1045.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (pre-vacination)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="260.9" lower_limit="122.0" upper_limit="557.8"/>
                    <measurement group_id="O2" value="164.7" lower_limit="47.5" upper_limit="571.3"/>
                    <measurement group_id="O3" value="328.7" lower_limit="200.5" upper_limit="538.8"/>
                    <measurement group_id="O4" value="1571.0" lower_limit="341.7" upper_limit="7222.1"/>
                    <measurement group_id="O5" value="505.2" lower_limit="275.8" upper_limit="925.4"/>
                    <measurement group_id="O6" value="1188.9" lower_limit="515.4" upper_limit="2742.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 70 (28 days after last vaccination)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="339.1" lower_limit="143.6" upper_limit="800.6"/>
                    <measurement group_id="O2" value="218.0" lower_limit="48.4" upper_limit="982.4"/>
                    <measurement group_id="O3" value="521.6" lower_limit="236.5" upper_limit="1150.3"/>
                    <measurement group_id="O4" value="2483.1" lower_limit="595.3" upper_limit="10357.2"/>
                    <measurement group_id="O5" value="970.3" lower_limit="553.4" upper_limit="1701.4"/>
                    <measurement group_id="O6" value="2170.4" lower_limit="1053.0" upper_limit="4473.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Unsolicited Adverse Events</title>
        <description>Adverse events were assessed for severity by the investigator according to the following:&#xD;
Mild (Grade 1): Does not interfere with routine activities Minimal level of discomfort&#xD;
Moderate (Grade 2): Interferes with routine activities Moderate level of discomfort&#xD;
Severe (Grade 3): Unable to perform routine activities Significant level of discomfort&#xD;
Potentially life-threatening (Grade 4): Hospitalization or emergency room (ER) visit for potentially life-threatening event</description>
        <time_frame>From first vaccination to 28 days after the third vaccination, 71 days.</time_frame>
        <population>All participants who received one or more doses of the study drugs</population>
        <group_list>
          <group group_id="O1">
            <title>Group A1: CssBA 5 µg</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA on days 1, 22, and 43.</description>
          </group>
          <group group_id="O2">
            <title>Group A2: DmLT 100 ng</title>
            <description>Participants received an intramuscular injection of 100 ng DmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O3">
            <title>Group B: CssBA 5 µg + DmLT 100 ng</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA co-administered with 100 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O4">
            <title>Group C: CssBA 5 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O5">
            <title>Group D: CssBA 15 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 15 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O6">
            <title>Group E: CssBA 45 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 45 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Unsolicited Adverse Events</title>
          <description>Adverse events were assessed for severity by the investigator according to the following:&#xD;
Mild (Grade 1): Does not interfere with routine activities Minimal level of discomfort&#xD;
Moderate (Grade 2): Interferes with routine activities Moderate level of discomfort&#xD;
Severe (Grade 3): Unable to perform routine activities Significant level of discomfort&#xD;
Potentially life-threatening (Grade 4): Hospitalization or emergency room (ER) visit for potentially life-threatening event</description>
          <population>All participants who received one or more doses of the study drugs</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Life-threatening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer of Serum Anti-LT Immunoglobulin G Antibodies</title>
        <description>Serum samples were assayed for IgG antibody titers against labile toxin using an enzyme-linked Immunosorbent assay (ELISA).</description>
        <time_frame>Days 1, 22, and 43 pre-vaccination, and Day 70</time_frame>
        <population>Participants who received at least 2 vaccine doses and had at least 2 post-vaccine samples available, and with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A1: CssBA 5 µg</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA on days 1, 22, and 43.</description>
          </group>
          <group group_id="O2">
            <title>Group A2: DmLT 100 ng</title>
            <description>Participants received an intramuscular injection of 100 ng DmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O3">
            <title>Group B: CssBA 5 µg + DmLT 100 ng</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA co-administered with 100 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O4">
            <title>Group C: CssBA 5 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O5">
            <title>Group D: CssBA 15 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 15 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O6">
            <title>Group E: CssBA 45 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 45 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer of Serum Anti-LT Immunoglobulin G Antibodies</title>
          <description>Serum samples were assayed for IgG antibody titers against labile toxin using an enzyme-linked Immunosorbent assay (ELISA).</description>
          <population>Participants who received at least 2 vaccine doses and had at least 2 post-vaccine samples available, and with available data at each time point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (pre-vaccination)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.1" lower_limit="16.4" upper_limit="129.7"/>
                    <measurement group_id="O2" value="25.1" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O3" value="84.5" lower_limit="31.8" upper_limit="224.0"/>
                    <measurement group_id="O4" value="88.9" lower_limit="54.0" upper_limit="146.5"/>
                    <measurement group_id="O5" value="75.0" lower_limit="37.4" upper_limit="150.4"/>
                    <measurement group_id="O6" value="48.8" lower_limit="25.0" upper_limit="95.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 (pre-vaccination)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.3" lower_limit="15.3" upper_limit="152.1"/>
                    <measurement group_id="O2" value="52.8" lower_limit="11.4" upper_limit="243.9"/>
                    <measurement group_id="O3" value="172.9" lower_limit="42.4" upper_limit="705.5"/>
                    <measurement group_id="O4" value="1010.3" lower_limit="182.9" upper_limit="5579.8"/>
                    <measurement group_id="O5" value="235.0" lower_limit="64.1" upper_limit="860.7"/>
                    <measurement group_id="O6" value="193.2" lower_limit="80.0" upper_limit="466.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (pre-vacination)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.3" lower_limit="15.8" upper_limit="136.0"/>
                    <measurement group_id="O2" value="303.7" lower_limit="39.8" upper_limit="2316.2"/>
                    <measurement group_id="O3" value="235.6" lower_limit="67.5" upper_limit="822.0"/>
                    <measurement group_id="O4" value="2671.0" lower_limit="754.2" upper_limit="9459.1"/>
                    <measurement group_id="O5" value="679.2" lower_limit="256.7" upper_limit="1797.0"/>
                    <measurement group_id="O6" value="666.8" lower_limit="339.7" upper_limit="1308.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 70 (28 days after last vaccination)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.0" lower_limit="17.8" upper_limit="170.1"/>
                    <measurement group_id="O2" value="398.1" lower_limit="91.9" upper_limit="1724.3"/>
                    <measurement group_id="O3" value="424.1" lower_limit="159.7" upper_limit="1126.6"/>
                    <measurement group_id="O4" value="3114.1" lower_limit="965.3" upper_limit="10046.6"/>
                    <measurement group_id="O5" value="1116.9" lower_limit="467.8" upper_limit="2666.7"/>
                    <measurement group_id="O6" value="1086.4" lower_limit="473.8" upper_limit="2491.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer of Serum Anti-LT Immunoglobulin A Antibodies</title>
        <description>Serum samples were assayed for IgA antibody titers against labile toxin using an enzyme-linked Immunosorbent assay (ELISA).</description>
        <time_frame>Days 1, 22, and 43 pre-vaccination, and Day 70</time_frame>
        <population>Participants who received at least 2 vaccine doses and had at least 2 post-vaccine samples available, and with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A1: CssBA 5 µg</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA on days 1, 22, and 43.</description>
          </group>
          <group group_id="O2">
            <title>Group A2: DmLT 100 ng</title>
            <description>Participants received an intramuscular injection of 100 ng DmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O3">
            <title>Group B: CssBA 5 µg + DmLT 100 ng</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA co-administered with 100 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O4">
            <title>Group C: CssBA 5 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O5">
            <title>Group D: CssBA 15 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 15 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O6">
            <title>Group E: CssBA 45 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 45 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer of Serum Anti-LT Immunoglobulin A Antibodies</title>
          <description>Serum samples were assayed for IgA antibody titers against labile toxin using an enzyme-linked Immunosorbent assay (ELISA).</description>
          <population>Participants who received at least 2 vaccine doses and had at least 2 post-vaccine samples available, and with available data at each time point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (pre-vaccination)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.1" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O2" value="25.1" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O3" value="28.4" lower_limit="21.4" upper_limit="37.7"/>
                    <measurement group_id="O4" value="25.8" lower_limit="24.2" upper_limit="27.6"/>
                    <measurement group_id="O5" value="28.6" lower_limit="21.3" upper_limit="38.5"/>
                    <measurement group_id="O6" value="25.1" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 (pre-vaccination)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.1" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O2" value="30.4" lower_limit="16.6" upper_limit="55.6"/>
                    <measurement group_id="O3" value="55.8" lower_limit="24.6" upper_limit="126.5"/>
                    <measurement group_id="O4" value="258.4" lower_limit="49.3" upper_limit="1352.9"/>
                    <measurement group_id="O5" value="77.8" lower_limit="35.3" upper_limit="171.3"/>
                    <measurement group_id="O6" value="134.6" lower_limit="57.0" upper_limit="317.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (pre-vacination)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.1" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O2" value="46.2" lower_limit="9.0" upper_limit="238.30"/>
                    <measurement group_id="O3" value="48.5" lower_limit="22.0" upper_limit="107.0"/>
                    <measurement group_id="O4" value="317.9" lower_limit="72.8" upper_limit="1388.5"/>
                    <measurement group_id="O5" value="75.9" lower_limit="33.6" upper_limit="171.4"/>
                    <measurement group_id="O6" value="159.6" lower_limit="62.8" upper_limit="405.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 70 (28 days after last vaccination)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.1" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O2" value="66.1" lower_limit="10.6" upper_limit="410.1"/>
                    <measurement group_id="O3" value="51.4" lower_limit="20.9" upper_limit="126.4"/>
                    <measurement group_id="O4" value="202.1" lower_limit="43.8" upper_limit="932.2"/>
                    <measurement group_id="O5" value="68.2" lower_limit="29.9" upper_limit="155.6"/>
                    <measurement group_id="O6" value="121.1" lower_limit="57.2" upper_limit="256.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer of Antibody Lymphocyte Supernatant Anti-CS6 Immunoglobulin G Antibodies</title>
        <description>Lymphocyte supernatant was assayed for IgG antibody titers against CS6 using ELISA.</description>
        <time_frame>Days 1, 8, 29 and 50</time_frame>
        <population>Participants who received at least 2 vaccine doses and had at least 2 post-vaccine samples available, and with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A1: CssBA 5 µg</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA on days 1, 22, and 43.</description>
          </group>
          <group group_id="O2">
            <title>Group A2: DmLT 100 ng</title>
            <description>Participants received an intramuscular injection of 100 ng DmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O3">
            <title>Group B: CssBA 5 µg + DmLT 100 ng</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA co-administered with 100 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O4">
            <title>Group C: CssBA 5 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O5">
            <title>Group D: CssBA 15 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 15 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O6">
            <title>Group E: CssBA 45 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 45 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer of Antibody Lymphocyte Supernatant Anti-CS6 Immunoglobulin G Antibodies</title>
          <description>Lymphocyte supernatant was assayed for IgG antibody titers against CS6 using ELISA.</description>
          <population>Participants who received at least 2 vaccine doses and had at least 2 post-vaccine samples available, and with available data at each time point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O2" value="4.0" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O3" value="4.0" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O4" value="5.7" lower_limit="2.5" upper_limit="12.8"/>
                    <measurement group_id="O5" value="4." lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O6" value="4.0" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 (7 days after 1st vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O2" value="4.0" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O3" value="5.0" lower_limit="2.9" upper_limit="8.6"/>
                    <measurement group_id="O4" value="14.9" lower_limit="3.2" upper_limit="70.3"/>
                    <measurement group_id="O5" value="8.5" lower_limit="2.7" upper_limit="26.6"/>
                    <measurement group_id="O6" value="7.1" lower_limit="3.0" upper_limit="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (7 days after 2nd vacination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="2.0" upper_limit="18.4"/>
                    <measurement group_id="O2" value="4.0" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O3" value="4.0" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O4" value="42.9" lower_limit="10.7" upper_limit="172.0"/>
                    <measurement group_id="O5" value="29.8" lower_limit="8.2" upper_limit="108.6"/>
                    <measurement group_id="O6" value="47.4" lower_limit="12.7" upper_limit="176.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (7 days after 3rd vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1" lower_limit="3.1" upper_limit="106.4"/>
                    <measurement group_id="O2" value="4.0" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O3" value="86.7" lower_limit="43.1" upper_limit="174.4"/>
                    <measurement group_id="O4" value="356.9" lower_limit="208.5" upper_limit="610.7"/>
                    <measurement group_id="O5" value="238.3" lower_limit="115.3" upper_limit="492.3"/>
                    <measurement group_id="O6" value="142.8" lower_limit="32.2" upper_limit="633.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer of Antibody Lymphocyte Supernatant Anti-CS6 Immunoglobulin A Antibodies</title>
        <description>Lymphocyte supernatant was assayed for IgA antibody titers against CS6 using ELISA.</description>
        <time_frame>Days 1, 8, 29, and 50</time_frame>
        <population>Participants who received at least 2 vaccine doses and had at least 2 post-vaccine samples available, and with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A1: CssBA 5 µg</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA on days 1, 22, and 43.</description>
          </group>
          <group group_id="O2">
            <title>Group A2: DmLT 100 ng</title>
            <description>Participants received an intramuscular injection of 100 ng DmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O3">
            <title>Group B: CssBA 5 µg + DmLT 100 ng</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA co-administered with 100 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O4">
            <title>Group C: CssBA 5 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O5">
            <title>Group D: CssBA 15 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 15 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O6">
            <title>Group E: CssBA 45 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 45 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer of Antibody Lymphocyte Supernatant Anti-CS6 Immunoglobulin A Antibodies</title>
          <description>Lymphocyte supernatant was assayed for IgA antibody titers against CS6 using ELISA.</description>
          <population>Participants who received at least 2 vaccine doses and had at least 2 post-vaccine samples available, and with available data at each time point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (pre-vaccination)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O2" value="2.5" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O3" value="2.5" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O4" value="2.5" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O5" value="2.5" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O6" value="2.5" lower_limit="2.5" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 (7 days after 1st vaccination)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O2" value="2.5" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O3" value="2.5" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O4" value="7.3" lower_limit="1.3" upper_limit="42.2"/>
                    <measurement group_id="O5" value="2.5" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O6" value="4.5" lower_limit="1.9" upper_limit="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (7 days after 2nd vacination)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O2" value="2.5" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O3" value="2.5" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O4" value="17.5" lower_limit="4.0" upper_limit="76.0"/>
                    <measurement group_id="O5" value="3.3" lower_limit="1.8" upper_limit="6.0"/>
                    <measurement group_id="O6" value="33.1" lower_limit="14.7" upper_limit="74.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (7 days after 3rd vaccination)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O2" value="2.5" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O3" value="6.4" lower_limit="2.1" upper_limit="19.6"/>
                    <measurement group_id="O4" value="46.6" lower_limit="13.8" upper_limit="157.2"/>
                    <measurement group_id="O5" value="24.1" lower_limit="8.5" upper_limit="68.7"/>
                    <measurement group_id="O6" value="35.2" lower_limit="17.4" upper_limit="71.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer of Antibody Lymphocyte Supernatant Anti-LT Immunoglobulin G Antibodies</title>
        <description>Lymphocyte supernatant was assayed for IgG antibody titers against labile toxin using ELISA.</description>
        <time_frame>Days 1, 8, 29, and 50</time_frame>
        <population>Participants who received at least 2 vaccine doses and had at least 2 post-vaccine samples available, and with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A1: CssBA 5 µg</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA on days 1, 22, and 43.</description>
          </group>
          <group group_id="O2">
            <title>Group A2: DmLT 100 ng</title>
            <description>Participants received 3 intramuscular injections of 100 ng DmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O3">
            <title>Group B: CssBA 5 µg + DmLT 100 ng</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA co-administered with 100 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O4">
            <title>Group C: CssBA 5 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O5">
            <title>Group D: CssBA 15 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 15 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O6">
            <title>Group E: CssBA 45 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 45 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer of Antibody Lymphocyte Supernatant Anti-LT Immunoglobulin G Antibodies</title>
          <description>Lymphocyte supernatant was assayed for IgG antibody titers against labile toxin using ELISA.</description>
          <population>Participants who received at least 2 vaccine doses and had at least 2 post-vaccine samples available, and with available data at each time point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O2" value="2.5" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O3" value="3.5" lower_limit="1.6" upper_limit="7.8"/>
                    <measurement group_id="O4" value="2.5" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O5" value="3.1" lower_limit="2.0" upper_limit="4.8"/>
                    <measurement group_id="O6" value="2.5" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 (7 days after 1st vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O2" value="2.5" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O3" value="6.6" lower_limit="1.5" upper_limit="29.2"/>
                    <measurement group_id="O4" value="24.0" lower_limit="6.0" upper_limit="97.0"/>
                    <measurement group_id="O5" value="47.4" lower_limit="8.7" upper_limit="258.8"/>
                    <measurement group_id="O6" value="17.6" lower_limit="5.0" upper_limit="61.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (7 days after 2nd vacination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O2" value="13.4" lower_limit="0.6" upper_limit="305.9"/>
                    <measurement group_id="O3" value="10.0" lower_limit="2.0" upper_limit="49.9"/>
                    <measurement group_id="O4" value="105.8" lower_limit="60.7" upper_limit="184.3"/>
                    <measurement group_id="O5" value="80.7" lower_limit="50.2" upper_limit="129.9"/>
                    <measurement group_id="O6" value="253.5" lower_limit="116.5" upper_limit="551.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (7 days after 3rd vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O2" value="88.1" lower_limit="48.2" upper_limit="161.0"/>
                    <measurement group_id="O3" value="70.0" lower_limit="41.5" upper_limit="117.9"/>
                    <measurement group_id="O4" value="138.4" lower_limit="102.0" upper_limit="187.7"/>
                    <measurement group_id="O5" value="123.3" lower_limit="100.0" upper_limit="152.0"/>
                    <measurement group_id="O6" value="187.5" lower_limit="101.9" upper_limit="345.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer of Antibody Lymphocyte Supernatant Anti-LT Immunoglobulin A Antibodies</title>
        <description>Lymphocyte supernatant was assayed for IgA antibody titers against labile toxin using ELISA.</description>
        <time_frame>Days 1, 8, 29, and 50</time_frame>
        <population>Participants who received at least 2 vaccine doses and had at least 2 post-vaccine samples available, and with available samples at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A1: CssBA 5 µg</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA on days 1, 22, and 43.</description>
          </group>
          <group group_id="O2">
            <title>Group A2: DmLT 100 ng</title>
            <description>Participants received an intramuscular injection of 100 ng DmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O3">
            <title>Group B: CssBA 5 µg + DmLT 100 ng</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA co-administered with 100 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O4">
            <title>Group C: CssBA 5 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 5 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O5">
            <title>Group D: CssBA 15 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 15 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
          <group group_id="O6">
            <title>Group E: CssBA 45 µg + DmLT 500 ng</title>
            <description>Participants received an intramuscular injection of 45 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer of Antibody Lymphocyte Supernatant Anti-LT Immunoglobulin A Antibodies</title>
          <description>Lymphocyte supernatant was assayed for IgA antibody titers against labile toxin using ELISA.</description>
          <population>Participants who received at least 2 vaccine doses and had at least 2 post-vaccine samples available, and with available samples at each time point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (pre-vaccination)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O2" value="2.0" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O3" value="2.0" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O4" value="2.8" lower_limit="1.3" upper_limit="5.9"/>
                    <measurement group_id="O5" value="2.0" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O6" value="2.0" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 (7 days after 1st vaccination)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O2" value="2.0" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O3" value="3.0" lower_limit="1.1" upper_limit="8.1"/>
                    <measurement group_id="O4" value="11.7" lower_limit="2.9" upper_limit="46.9"/>
                    <measurement group_id="O5" value="12.7" lower_limit="3.8" upper_limit="42.8"/>
                    <measurement group_id="O6" value="9.0" lower_limit="2.8" upper_limit="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (7 days after 2nd vacination)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O2" value="9.9" lower_limit="0.5" upper_limit="198.1"/>
                    <measurement group_id="O3" value="4.1" lower_limit="1.4" upper_limit="12.4"/>
                    <measurement group_id="O4" value="28.7" lower_limit="8.8" upper_limit="93.9"/>
                    <measurement group_id="O5" value="19.3" lower_limit="7.9" upper_limit="47.3"/>
                    <measurement group_id="O6" value="60.5" lower_limit="44.9" upper_limit="81.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (7 days after 3rd vaccination)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as the variance was zero</measurement>
                    <measurement group_id="O2" value="13.3" lower_limit="1.6" upper_limit="107.6"/>
                    <measurement group_id="O3" value="3.6" lower_limit="1.4" upper_limit="9.5"/>
                    <measurement group_id="O4" value="24.7" lower_limit="7.6" upper_limit="80.0"/>
                    <measurement group_id="O5" value="23.6" lower_limit="8.5" upper_limit="65.4"/>
                    <measurement group_id="O6" value="18.7" lower_limit="5.8" upper_limit="60.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the day of the first vaccination up to 28 days after the third vaccination, 71 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group A1: CssBA 5 µg</title>
          <description>Participants received an intramuscular injection of 5 µg CssBA on days 1, 22, and 43.</description>
        </group>
        <group group_id="E2">
          <title>Group A2: DmLT 100 ng</title>
          <description>Participants received an intramuscular injection of 100 ng DmLT on days 1, 22, and 43.</description>
        </group>
        <group group_id="E3">
          <title>Group B: CssBA 5 µg + DmLT 100 ng</title>
          <description>Participants received an intramuscular injection of 5 µg CssBA co-administered with 100 ng dmLT on days 1, 22, and 43.</description>
        </group>
        <group group_id="E4">
          <title>Group C: CssBA 5 µg + DmLT 500 ng</title>
          <description>Participants received an intramuscular injection of 5 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
        </group>
        <group group_id="E5">
          <title>Group D: CssBA 15 µg + DmLT 500 ng</title>
          <description>Participants received an intramuscular injection of 15 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
        </group>
        <group group_id="E6">
          <title>Group E: CssBA 45 µg + DmLT 500 ng</title>
          <description>Participants received an intramuscular injection of 45 µg CssBA co-administered with 500 ng dmLT on days 1, 22, and 43.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivital hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hemorroidal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Axillary Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hangover</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vaccination Site Bruising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vessel Puncture Site Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vessel Puncture Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vaccination Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vaccination Site Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vaccination Site Discoloration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vaccination Site Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vaccination Site Induration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vaccination Site Papule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vaccination Site Swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vaginal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Viral Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lower Limb Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Skin Abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vitamin D Deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Diastolic Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Systolic Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rahsan Erdem</name_or_title>
      <organization>PATH</organization>
      <phone>202-540-4546</phone>
      <email>rerdem@path.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

